glp-1 long beach Program Nuviva Medical Weight Loss Clinic

[PubMed Central ID: PMC4058735]

Leung C, Rivera L, Furness JB, Angus PW

According to Lilly, retatrutide is not yet available to the public, is not FDA-approved, and is still being studied in Phase 3 trials

Safety Considerations & Screening Protocols Both Medvi and compounded-GLP-1 pathways require baseline screening for contraindications: personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia type 2 (MEN2), severe pancreatitis, or diabetic retinopathy

GLP-1 receptor agonists are not recommended during pregnancy or breastfeeding and are not indicated for type 1 diabetes

Patients should discuss reproductive planning with their healthcare provider before starting either medication